- Home
- VINP vs KROS Comparison
VINP vs KROS Comparison
Compare VINP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | KROS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 584.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VINP | KROS |
|---|---|---|
| Price | $10.16 | $11.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $14.00 | ★ $22.25 |
| AVG Volume (30 Days) | 73.2K | ★ 376.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $13.97 | N/A |
| P/E Ratio | $24.41 | ★ $4.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $9.12 |
| 52 Week High | $13.61 | $22.55 |
Technical Indicators
Market Signals| Indicator | VINP | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 23.09 | 17.12 |
| Support Level | $9.25 | N/A |
| Resistance Level | $10.87 | $15.21 |
| Average True Range (ATR) | 0.60 | 0.71 |
| MACD | -0.18 | -0.22 |
| Stochastic Oscillator | 0.19 | 7.37 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.